Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
10.07
+0.04 (0.40%)
Feb 24, 2026, 4:00 PM EST - Market closed
Karyopharm Therapeutics Revenue
In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth. Karyopharm Therapeutics had revenue of $34.08M in the quarter ending December 31, 2025, with 11.58% growth.
Revenue (ttm)
$146.07M
Revenue Growth
+0.57%
P/S Ratio
1.26
Revenue / Employee
$523,538
Employees
279
Market Cap
184.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Editas Medicine | 46.38M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Fate Therapeutics | 7.14M |
| Cartesian Therapeutics | 1.09M |
| Molecular Partners AG | 856.30K |
| SAB Biotherapeutics | 114.70K |
KPTI News
- 12 days ago - Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 20 days ago - Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - PRNewsWire
- 22 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - PRNewsWire
- 2 months ago - Karyopharm to Participate in Baird's Biotech Discovery Series - PRNewsWire
- 3 months ago - Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 4 months ago - Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript - Seeking Alpha